Skip to main content

Clinical development partner

Menu
immunology & vaccines

Immunology & Vaccines

World-class scientific depth for immunology & vaccines

Vaccine and immunology programs demand both scientific authority and global operational reach. CR2O combines an advisory network including Prof. Ab Osterhaus with sites and Phase I units across Europe, Asia and Africa, for challenge studies, adjuvant trials and complex immunotherapy programs.

Our global footprint in immunology & infectious disease

Our experience spans the full clinical development pathway in infectious diseases and immunology, from early-phase vaccine and therapeutic programmes to Phase IV studies. We have worked across both established and emerging infections, as well as complex immune-mediated and rare genetic disorders, with access to diverse patient populations and specialised study sites across multiple geographies. This breadth enables us to adapt clinical strategies to the scientific, operational and regulatory requirements of each programme.

COVID-19

Phase I–III
Vaccine studies · Netherlands, South Africa

Influenza

Phase I–II
Vaccine studies & CHIM · Netherlands, Belgium

RSV

Phase I
Vaccine study · Netherlands

Malaria

Phase Ib
Vaccine study · Netherlands

MERS

Phase Ib–II
Vaccine studies · Netherlands, Germany, Saudi Arabia

HIV

Phase II
Vaccine study · Netherlands, Belgium, Spain

Rift Valley Fever

Phase I–II
Vaccine studies · Belgium, Kenya, Uganda

Lyme borreliosis

Phase I–II
Vaccine studies · Belgium

Polio

Phase IV
Vaccine studies · Belgium

Rabies

Phase I
Vaccine studies · Belgium

Rheumatoid arthritis

Phase II & IV
Immunology studies · Netherlands, Germany, Portugal, Italy, Romania, Slovenia, Finland, Hungary, Georgia

SLE, vasculitis & IPF

Phase I
Immunology study · Netherlands

Idiopathic pulmonary fibrosis

Phase II
Pulmonary study · Belgium

RAG1-deficient SCID

Phase I
Cell & gene therapy · Poland, Turkey, Netherlands

Explore

Where we support immunology & vaccine sponsors

Guided by Prof. Ab Osterhaus and a bench of immunology KOLs.

  • Program design for prophylactic and therapeutic vaccines
  • Adjuvant, delivery system and platform evaluation
  • Regulatory strategy including WHO PQ pathways
Access to specialist units for controlled human infection models.
  • Influenza, RSV and emerging pathogen models
  • BSL-3 partner sites and quarantine facilities
  • Endpoint immunology and viral shedding analytics
Touchpoints across Europe, Asia, Africa and Latin America.
  • Vaccine trial sites with pediatric and geriatric experience
  • Partnerships with university hospitals and specialist vaccine sites
  • Cold-chain and IMP logistics coordinated end-to-end
Endpoint assays, biomarker panels and correlate-of-protection design.
  • Central lab orchestration and bioanalytical strategy
  • Cellular and humoral immunity panels
  • Statistical support for correlate-of-protection analyses

Design your trial

Ready to design your vaccine or immunology trial?

Talk with our scientific team about your target profile. We’ll return with a study concept, site shortlist and budget.

Send us an e-mail